Institute of Physiological Chemistry, Faculty of Medicine, Philipps-University of Marburg, Karl-von-Frisch-Straße 1, 35032 Marburg, Germany; Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École polytechnique fédérale de Lausanne (EPFL), Station 19, 1015 Lausanne, Switzerland.
Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, 522 1st Avenue, New York, NY 10016, USA.
Curr Opin Struct Biol. 2020 Feb;60:167-174. doi: 10.1016/j.sbi.2020.01.015. Epub 2020 Mar 4.
Monobodies, built with the scaffold of the fibronectin type III domain, are among the most well-established synthetic binding proteins. They promote crystallization of challenging molecular systems. They have strong tendency to bind to functional sites and thus serve as drug-like molecules that perturb the biological functions of their targets. Monobodies lack disulfide bonds and thus they are particularly suited as genetically encoded reagents to be used intracellularly. This article reviews recent monobody-enabled studies that reveal new structures, molecular mechanisms and potential therapeutic opportunities. A systematic analysis of the crystal structures of monobody-target complexes suggests important attributes that make monobodies effective crystallization chaperones.
单域抗体,基于纤连蛋白 III 结构域的支架构建,是最成熟的合成结合蛋白之一。它们促进具有挑战性的分子系统的结晶。它们具有强烈结合功能位点的趋势,因此作为类似药物的分子,干扰其靶标的生物学功能。单域抗体缺乏二硫键,因此特别适合作为遗传编码试剂在细胞内使用。本文综述了最近的单域抗体研究,揭示了新的结构、分子机制和潜在的治疗机会。对单域抗体-靶标复合物晶体结构的系统分析表明,单域抗体作为有效的结晶伴侣具有重要的属性。